

## GlaxoSmithKline (UK Ltd) and NHS Greater Glasgow and Clyde Executive Summary

### COPD Optimisation in Greater Glasgow and Clyde

This summary has been written by GSK with consultation and approval from the Joint Working Project Team.

NHS Greater Glasgow and Clyde and GSK are undertaking a Joint Working project. The aims are to:

- Align to Greater Glasgow and Clyde 'COPD inhaler device guide', focussing on patients with risk factors for review and optimisation in line with 'Guidelines'
- Align to 'Recover, Restore, Renew' (Scotland Chief Medical Officer's 2021 report highlighting areas of good practice and innovation) to reduce the use of MDIs across GGC where clinically appropriate.
- Increase awareness and uptake/usage of all non pharmacological interventions already available and established across the health board e.g pulmonary rehabilitation, vaccinations, smoking cessation and Dynamic Scot digital service (Dynamic Scot pre-dates this Joint Working Agreement, created by the NHS and was already available to patients)

This involves a balance of contributions from both parties with the pooling of skills, experience and resources. The project will run from May 2022 to April 2023.

GSK will fund patient reviews and access to Quality Improvement software- EQIpped via Interface Clinical Services (ICS) Ltd in up to 40 practices at an approximate cost of £8,869 per practice, to a total of approximately £354,797. An additional 10 practices may have access to EQIpped only at an approximate cost of £1,711 per practice, to a total cost of 17,112. In addition, GSK will contribute a total of approximately £17,200 in indirect costs such as colleagues' time across the project. GSK will not have any influence over treatment decisions. GSK will not have access to patient medical records or personal information.

The NHS will contribute up to approximately 3258 hours of resource across primary care colleagues' time and ICB project management time at an approximate indirect cost of £4,549 per practice in up to 50 practices, to a total of approximately £227,455.50. The NHS contribution to the project does not include any transfer of money, it is based on the approximate costs of resource allocation.

#### Intended Benefits:

Patients	<ul style="list-style-type: none"><li>• Full COPD review in line with local guidelines based on risk stratification (patients may have not received a review otherwise or will receive quicker than when reviewed in yearly cycle) potentially increasing volume of those receiving a review, potentially leading to better outcomes</li><li>• Optimisation of both non-pharmacological &amp; pharmacological management</li><li>• Potentially fewer COPD- related interventions, including hospital admissions</li><li>• Better informed about COPD management and treatment options</li><li>• COPD managed in accordance with current best practice clinical guidance</li></ul>
NHS	<ul style="list-style-type: none"><li>• Realisation of value-based healthcare objectives of improved patient outcomes with reduced costs.</li><li>• Support with risk stratification</li><li>• Additional resource support</li><li>• Guideline implementation resulting in consistent prescribing and non-prescribing recommendations and promoting learning for sustainability</li><li>• Insight into COPD population at practice and local healthcare economy level to allow sharing best practice and evaluation of care provision to support clinical governance and support equity of care</li><li>• Opportunity to upskill primary care doctors and nurses</li><li>• An environment to support the delivery of improved health outcomes for the COPD patient population</li></ul>

**GlaxoSmithKline (UK Ltd) and NHS Greater Glasgow and Clyde Executive Summary**

	<ul style="list-style-type: none"> <li>• Potential reduction in COPD- related interventions, including hospital admissions</li> <li>• Build network of respiratory interested health care professionals</li> <li>• Prescribing in-line with national sustainability aspirations where clinically appropriate for patients</li> </ul>
GSK	<ul style="list-style-type: none"> <li>• Broadening of the professional network</li> <li>• Demonstrate partnership working</li> <li>• In line with the sustainability agenda, there may be a potential increase in prescribing of on formulary DPI products within class if clinically appropriate for patients – which may include GSK products</li> <li>• Expansion of the COPD patient population who are managed according to current clinical and best practice guidelines as a result of the programme</li> <li>• Increase in the appropriate use of medicines licensed for COPD aligned to local guidance, will likely increase the prescribing of GSK products as well as those of other pharmaceutical companies.</li> <li>• Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care</li> <li>• Helps GSK to live its value of being a patient focussed company</li> </ul>